CN Patent

CN117915901A — 氘代丁苯那嗪和cyp2d6抑制剂的联合施用方法

Assigned to Neurocrine Biosciences Inc · Expires 2024-04-19 · 2y expired

What this patent protects

提供治疗有需要的患者中的神经或精神疾病或病症的方法，所述方法包括：向所述有需要的患者施用囊泡单胺转运蛋白2(VMAT2)抑制剂，所述患者还正在被施用强细胞色素P450 2D6(CYP2D6)抑制剂。

USPTO Abstract

提供治疗有需要的患者中的神经或精神疾病或病症的方法，所述方法包括：向所述有需要的患者施用囊泡单胺转运蛋白2(VMAT2)抑制剂，所述患者还正在被施用强细胞色素P450 2D6(CYP2D6)抑制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN117915901A
Jurisdiction
CN
Classification
—
Expires
2024-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Neurocrine Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.